liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Bisphosphonate Use and Atypical Fractures of the Femoral Shaft
Linköping University, Faculty of Health Sciences. Linköping University, Department of Clinical and Experimental Medicine, Orthopaedics.
Uppsala University.
Linköping University, Department of Clinical and Experimental Medicine, Orthopaedics and Sports Medicine. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Centre for Surgery, Orthopaedics and Cancer Treatment, Department of Orthopaedics in Linköping.
2011 (English)In: NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, Vol. 364, no 18, 1728-1737 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND Studies show conflicting results regarding the possible excess risk of atypical fractures of the femoral shaft associated with bisphosphonate use. METHODS In Sweden, 12,777 women 55 years of age or older sustained a fracture of the femur in 2008. We reviewed radiographs of 1234 of the 1271 women who had a subtrochanteric or shaft fracture and identified 59 patients with atypical fractures. Data on medications and coexisting conditions were obtained from national registries. The relative and absolute risk of atypical fractures associated with bisphosphonate use was estimated by means of a nationwide cohort analysis. The 59 case patients were also compared with 263 control patients who had ordinary subtrochanteric or shaft fractures. RESULTS The age-adjusted relative risk of atypical fracture was 47.3 (95% confidence interval [CI], 25.6 to 87.3) in the cohort analysis. The increase in absolute risk was 5 cases per 10,000 patient-years (95% CI, 4 to 7). A total of 78% of the case patients and 10% of the controls had received bisphosphonates, corresponding to a multivariable-adjusted odds ratio of 33.3 (95% CI, 14.3 to 77.8). The risk was independent of coexisting conditions and of concurrent use of other drugs with known effects on bone. The duration of use influenced the risk (odds ratio per 100 daily doses, 1.3; 95% CI, 1.1 to 1.6). After drug withdrawal, the risk diminished by 70% per year since the last use (odds ratio, 0.28; 95% CI, 0.21 to 0.38). CONCLUSIONS These population-based nationwide analyses may be reassuring for patients who receive bisphosphonates. Although there was a high prevalence of current bisphosphonate use among patients with atypical fractures, the absolute risk was small.

Place, publisher, year, edition, pages
Massachusetts Medical Society , 2011. Vol. 364, no 18, 1728-1737 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-68216DOI: 10.1056/NEJMoa1010650ISI: 000290219800009OAI: diva2:416875
Available from: 2011-05-13 Created: 2011-05-13 Last updated: 2012-03-25

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Schilcher, JörgAspenberg, Per
By organisation
Faculty of Health SciencesOrthopaedicsOrthopaedics and Sports MedicineDepartment of Orthopaedics in Linköping
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 63 hits
ReferencesLink to record
Permanent link

Direct link